Physician-Scientist with Proven Track Record of Global Drug Development and Regulatory Approvals to Lead Clinical Development of IGI’s Multispecific™ Oncology Pipeline ...
Today, we get our first look at IGI: Origins, the first new title in the IGI series in well over a decade. You may remember IGI: Origins from a modest reveal from earlier in the year. This is indeed ...
NEW YORK and NORTH CHICAGO, Ill., July 10, 2025 /PRNewswire/ -- IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE: ABBV) today ...
AbbVie has acquired global rights to the lead pipeline asset of Ichnos Glenmark Innovation (IGI), the cancer and autoimmune disease candidate ISB 2001, now in development against multiple myeloma, ...
NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ichnos Glenmark Innovation (IGI), an alliance between Ichnos Sciences Inc., a global fully integrated clinical-stage biotech company developing ...
Ichnos Glenmark Innovation subsidiary IGI Therapeutics has signed an exclusive licensing agreement with AbbVie for ISB 2001, a cluster of differentiation 38 (CD38) B-cell maturation antigen (BCMA) and ...
In an upshot for Indian innovation, drugmaker Glenmark Pharmaceutical’s wholly-owned subsidiary Ichnos Glenmark Innovation Inc (IGI) has signed an exclusive licensing agreement with US drugmaker ...
NEW YORK and NORTH CHICAGO, Ill., July 10, 2025 (GLOBE NEWSWIRE) -- IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE: ABBV) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results